NUAK1 (ARK5) Is Associated with Poor Prognosis in Ovarian Cancer

摘要

Background and objective Nua kinase 1 (NUAK1) was identified in multigene signatures of survival and suboptimal debulking in high-grade serous ovarian cancer (HGSOC). This study investigates the individual clinical and biologic contributions of NUAK1 in HGSOC patients and cell lines. Methods Public transcript expression, clinical, and outcome data were used to interrogate the relationship between NUAK1 and clinicopathologic factors and patient outcomes including progression-free survival (PFS) and molecular subtypes using logistic and Cox modeling. Analysis of NUAK1 transcript expression was performed in primary tumors from 34 HGSOC patients with < or ≥2?years PFS. The impact of silencing NUAK1 by RNA interference (RNAi) on the migratory potential and chemosensitivity of SOC cells was assessed in vitro . Results Elevated NUAK1 transcript expression was associated with worse PFS (hazard ratio?=?1.134), advanced stage (odds ratio, OR?=?1.7), any residual disease (OR?=?1.58), and mesenchymal disease subtype (OR?=?7.79?±?5.89). Elevated NUAK1 transcript expression was observed in HGSOC patients with < vs. ≥2?years PFS ( p ?